Biologic and protective properties of the 69-kDa outer membrane protein of Bordetella pertussis: a novel formulation for an acellular pertussis vaccine
- PMID: 2056199
- DOI: 10.1093/infdis/164.1.114
Biologic and protective properties of the 69-kDa outer membrane protein of Bordetella pertussis: a novel formulation for an acellular pertussis vaccine
Abstract
A combination of the 69-kDa outer membrane protein and filamentous hemagglutinin (FHA), both isolated from lymphocytosis promoting factor (LPF; pertussis toxin) minus mutants of Bordetella pertussis, is protective in the mouse intracerebral challenge potency (Kendrick) test. A combination of the same 69-kDa protein and LPF is approximately 15 times less effective. These data suggest that, surprisingly, the 69-kDa protein in tandem with FHA is the most relevant combination for mouse protection; consequently such a combination may be a more suitable acellular pertussis vaccine candidate than the LPF/FHA combinations, which have never been satisfactorily protective in the mouse test. Preparation of samples of the 69-kDa protein of acceptable protective quality remains difficult. Attempts were made to screen the most suitable batches of the preparations by exploiting some recently discovered properties of the 69-kDa protein: the characteristic chromatofocusing pattern of the protein, the affinity for lymphocytes, and the ability to bind to nicotinamide adenine dinucleotide. None of these tests was able to replace the mouse intracerebral challenge potency test for final quality assessment.
Similar articles
-
A novel bivalent acellular pertussis vaccine based on the 69 kDa protein and FHA.Dev Biol Stand. 1991;73:243-9. Dev Biol Stand. 1991. PMID: 1778316
-
Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis.Clin Exp Immunol. 2006 Jun;144(3):543-51. doi: 10.1111/j.1365-2249.2006.03097.x. Clin Exp Immunol. 2006. PMID: 16734625 Free PMC article.
-
Protective activities of the filamentous hemagglutinin and the lymphocytosis-promoting factor of Bordetella pertussis in mice.J Infect Dis. 1984 Dec;150(6):823-33. doi: 10.1093/infdis/150.6.823. J Infect Dis. 1984. PMID: 6094673
-
A consideration of control requirements for acellular pertussis vaccines.Dev Biol Stand. 1997;89:343-7. Dev Biol Stand. 1997. PMID: 9272369 Review. No abstract available.
-
Molecular aspects of Bordetella pertussis pathogenesis.Int Microbiol. 1999 Sep;2(3):137-44. Int Microbiol. 1999. PMID: 10943406 Review.
Cited by
-
Bordetella bronchiseptica-mediated cytotoxicity to macrophages is dependent on bvg-regulated factors, including pertactin.Infect Immun. 1999 Nov;67(11):5972-8. doi: 10.1128/IAI.67.11.5972-5978.1999. Infect Immun. 1999. PMID: 10531256 Free PMC article.
-
Pertactin is required for Bordetella species to resist neutrophil-mediated clearance.Infect Immun. 2010 Jul;78(7):2901-9. doi: 10.1128/IAI.00188-10. Epub 2010 Apr 26. Infect Immun. 2010. PMID: 20421378 Free PMC article.
-
Pathogen proteins eliciting antibodies do not share epitopes with host proteins: a bioinformatics approach.PLoS One. 2007 Jun 6;2(6):e512. doi: 10.1371/journal.pone.0000512. PLoS One. 2007. PMID: 17551592 Free PMC article.
-
Adjuvanticity and protective immunity elicited by Bordetella pertussis antigens encapsulated in poly(DL-lactide-co-glycolide) microspheres.Infect Immun. 1995 Apr;63(4):1195-200. doi: 10.1128/iai.63.4.1195-1200.1995. Infect Immun. 1995. PMID: 7890372 Free PMC article.
-
Safety and efficacy of a Bordetella bronchiseptica outer membrane proteins (OMPs) subunit vaccine in a murine model.J Vet Sci. 2025 May;26(3):e39. doi: 10.4142/jvs.25018. J Vet Sci. 2025. PMID: 40461428 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical